Anti-diabetic activities of jiaotaiwan in db/db mice by augmentation of AMPK protein activity and upregulation of GLUT4 expression

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Hu, Na ^a   Yuan, Lin ^a   Li, Hui Jiao ^a   Huang, Cheng ^a   Mao, Quan Ming ^a   Zhang, Yong Yu ^a   Lin, Min ^a   Sun, Yin Qiang ^a   Zhong, Xiao Yu ^a   Tang, Peng ^a   Lu, Xiong ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CINNAMON EXTRACT; COPTIS CHINENSIS EXTRACT; GLUCOSE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; JIAOTAIWAN; PLANT MEDICINAL PRODUCT; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CHINESE MEDICINE; CINNAMON; CONTROLLED STUDY; COPTIS CHINENSIS; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; INSULIN BLOOD LEVEL; INSULIN TOLERANCE TEST; LIVER; MOUSE; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SKELETAL MUSCLE;

EID: 84879306625     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/180721     Document Type: Article

References (29)

1. Jia Q., Liu X., Wu X., Wang R., Hu X., Li Y., Huang C., Hypoglycemic activity of a polyphenolic oligomer-rich extract of Cinnamomum parthenoxylon bark in normal and streptozotocin-induced diabetic rats. Phytomedicine 2009 16 8 744 750 2-s2.0-67349229553 10.1016/j.phymed.2008.12.012
2. Chan J. C. N., Malik V., Jia W., Kadowaki T., Yajnik C. S., Yoon K. H., Hu F. B., Diabetes in Asia: epidemiology, risk factors, and pathophysiology. Journal of the American Medical Association 2009 301 20 2129 2140 2-s2.0-66149131064 10.1001/jama.2009.726
3. Chiang C. K., Ho T. I., Peng Y. S., Hsu S. P., Pai M. F., Yang S. Y., Hung K. Y., Wu K. D., Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care 2007 30 1 3 7 2-s2.0-33846003119 10.2337/dc06-0956
4. Chen H. Y., Ye X. L., Cui X. L., He K., Jin Y. N., Chen Z., Li X. G., Cytotoxicity and antihyperglycemic effect of minor constituents from Rhizoma coptis in HepG2 cells. Fitoterapia 2012 83 1 67 73 10.1016/j.fitote.2011.09.014
5. Zimmermann G. R., Lehár J., Keith C. T., Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discovery Today 2007 12 1-2 34 42 2-s2.0-33845762340 10.1016/j.drudis.2006.11. 008
6. Kwon K. B., Kim E. K., Jeong E. S., Lee Y. H., Lee Y. R., Park J. W., Ryu D. G., Park B. H., Cortex cinnamomi extract prevents streptozotocin- and cytokine-induced β -cell damage by inhibiting NF- B. World Journal of Gastroenterology 2006 12 27 4331 4337 2-s2.0-33746911644
7. Khan A., Safdar M., Khan M. M. A., Khattak K. N., Anderson R. A., Cinnamon improves glucose and lipids of people with type 2 diabetes. Diabetes Care 2003 26 12 3215 3218 2-s2.0-0345707504 10.2337/diacare.26.12.3215
8. Huang C., Zhang Y., Gong Z., Sheng X., Li Z., Zhang W., Qin Y., Berberine inhibits 3T3-L1 adipocyte differentiation through the PPAR γ pathway. Biochemical and Biophysical Research Communications 2006 348 2 571 578 2-s2.0-33747079990 10.1016/j.bbrc.2006.07.095
9. Wang Y., Campbell T., Perry B., Beaurepaire C., Qin L., Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats. Metabolism 2011 60 2 298 305 2-s2.0-78751647742 10.1016/j.metabol.2010.02.005
10. Yin J., Xing H., Ye J., Efficacy ofberberine in patients with type 2 diabetes mellitus. Metabolism 2008 57 5 712 717 10.1016/j.metabol.2008.01.013
11. Subash Babu P., Prabuseenivasan S., Ignacimuthu S., Cinnamaldehyde-a potential antidiabetic agent. Phytomedicine 2007 14 1 15 22 2-s2.0-33845624872 10.1016/j.phymed.2006.11.005
12. Gong Y., Lu F., Dong H., Xu L., Wang J., Zou X., Chen G., Therapeutic effect of Jiaotaiwan and its single components for the treatment of type 2 diabetes mellitus in rats. Chinese Journal of Hospital Pharmacy 2010 30 5
13. Steinberg G. R., Kemp B. E., AMPK in health and disease. Physiological Reviews 2009 89 3 1025 1078 2-s2.0-67650914230 10.1152/physrev.00011.2008
14. Stöckli J., Fazakerley D. J., James D. E., GLUT4 exocytosis. Journal of Cell Science 2011 124 4147 4159 10.1242/jcs.097063
15. Dela F., Ploug T., Handberg A., Petersen L. N., Larsen J. J., Mikines K. J., Galbo H., Physical training increases muscle GLUT4 protein and mRNA in patients with NIDDM. Diabetes 1994 43 7 862 865 2-s2.0-0028200755
16. Takahashi Y., Ide T., Dietary n-3 fatty acids affect mRNA level of brown adipose tissue uncoupling protein 1, and white adipose tissue leptin and glucose transporter 4 in the rat. British Journal of Nutrition 2000 84 2 175 184 2-s2.0-0033844398
17. Osei K., Rhinesmith S., Gaillard T., Schuster D., Impaired insulin sensitivity, insulin secretion, and glucose effectiveness predict future development of impaired glucose tolerance and type 2 diabetes in pre-diabetic African Americans: Implications for primary diabetes prevention. Diabetes Care 2004 27 6 1439 1446 2-s2.0-2542501028 10.2337/diacare.27.6.1439
18. Chan K. M., Raikwar S. P., Zavazava N., Strategies for differentiating embryonic stem cells (ESC) into insulin-producing cells and development of non-invasive imaging techniques using bioluminescence. Immunologic Research 2007 39 1-3 261 270 2-s2.0-35348816755 10.1007/s12026-007-0070-7
19. Sriwijitkamol A., Coletta D. K., Wajcberg E., Balbontin G. B., Reyna S. M., Barrientes J., Eagan P. A., Jenkinson C. P., Cersosimo E., DeFronzo R. A., Sakamoto K., Musi N., Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study. Diabetes 2007 56 3 836 848 2-s2.0-33847399214 10.2337/db06-1119
20. Mcgee S. L., Hargreaves M., Exercise and skeletal muscle glucose transporter 4 expression: molecular mechanisms. Clinical and Experimental Pharmacology and Physiology 2006 33 4 395 399 10.1111/j.1440-1681.2006.04362.x
21. Noguchi H., Xu G., Matsumoto S., Kaneto H., Kobayashi N., Bonner-Weir S., Hayashi S., Induction of pancreatic stem/progenitor cells into insulin-producing cells by adenoviral-mediated gene transfer technology. Cell Transplantation 2006 15 10 929 938 2-s2.0-33846639665 10.3727/000000006783981431
22. Koya V., Lu S., Sun Y. P., Purich D. L., Atkinson M. A., Li S. W., Yang L. J., Reversal of streptozotocin-induced diabetes in mice by cellular transduction with recombinant pancreatic transcription factor pancreatic duodenal homeobox-1 a novel protein transduction domain-based therapy. Diabetes 2008 57 3 757 769 2-s2.0-40949136580 10.2337/db07-1441
23. Lehrke M., Lazar M. A., The many faces of PPAR γ Cell 2005 123 6 993 999 10.1016/j.cell.2005.11.026
24. Wang Y. X., PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Research 2010 20 2 124 137 10.1038/cr.2010.13
25. Rosen E. D., Sarraf P., Troy A. E., Bradwin G., Moore K., Milstone D. S., Spiegelman B. M., Mortensen R. M., PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Molecular Cell 1999 4 4 611 617 2-s2.0-0033213631 10.1016/S1097-2765(00)80211-7
26. Hu E., Tontonoz P., Spiegelman B. M., Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR γ and C/EBP α Proceedings of the National Academy of Sciences of the United States of America 1995 92 21 9856 9860 2-s2.0-0028871780 10.1073/pnas.92.21.9856
27. Moller D. E., New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001 414 6865 821 827 2-s2.0-0035857020 10.1038/414821a
28. Koo S. H., Flechner L., Qi L., Zhang X., Screaton R. A., Jeffries S., Hedrick S., Xu W., Boussouar F., Brindle P., Takemori H., Montminy M., The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005 437 7062 1109 1114 2-s2.0-27144506185 10.1038/nature03967
29. Burcelin R., Crivelli V., Perrin C., Da Costa A., Mu J., Kahn B. B., Birnbaum M. J., Kahn C. R., Vollenweider P., Thorens B., GLUT4, AMP kinase, but not the insulin receptor, are required for hepatoportal glucose sensor-stimulated muscle glucose utilization. Journal of Clinical Investigation 2003 111 10 1555 1562 2-s2.0-0038651914 10.1172/JCI200316888